Anterior Iliopsoas Muscle Space Block Versus Supra-iliac Anterior Quadratus Lumborum Block in Total Hip Arthroplasty
Launched by ZAGAZIG UNIVERSITY · Sep 22, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different methods of providing pain relief for patients undergoing total hip arthroplasty (THA), which is surgery to replace a damaged hip joint. The researchers want to compare the effectiveness of the anterior iliopsoas muscle space block and the supra-iliac anterior quadratus lumborum block in helping manage pain after surgery. This is important because many patients experience significant pain after hip surgery, which can slow down their recovery and ability to move around.
To participate in this study, you need to be between 50 and 80 years old, have a body mass index (BMI) of 30 or lower, and be scheduled for elective hip surgery under general anesthesia. The trial is currently looking for participants, and if you join, you can expect to receive one of the pain relief methods being studied before your surgery. It's essential to know that certain medical conditions and allergies may prevent you from participating, so talk to your doctor if you're interested. This trial aims to improve pain management and enhance recovery for hip surgery patients, helping them get back to their daily activities more quickly.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient acceptance.
- • Age 50-80 years old.
- • BMI ≤ 30 kg/m2
- • ASA I - III.
- • Elective total hip arthroplasty under general anesthesia.
- Exclusion Criteria:
- • History of allergy to the LA agents used in this study
- • Skin lesion at the needle insertion site,
- • Those with bleeding disorders, sepsis, liver disease, and psychiatric disorders
- • Pre-existing neurological deficit in the lower extremity
- • History of chronic pain and taking analgesics
- • History of cognitive dysfunction or mental illness
About Zagazig University
Zagazig University, a prominent educational and research institution located in Egypt, plays a pivotal role in advancing medical knowledge and promoting health innovations through its clinical trials. With a commitment to excellence in research, the university leverages its diverse expertise and state-of-the-art facilities to conduct rigorous clinical studies that aim to improve patient care and outcomes. By fostering collaboration among multidisciplinary teams, Zagazig University contributes significantly to the global medical community, ensuring that its clinical trials adhere to the highest ethical standards and regulatory requirements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zagazig, Alsharqia, Egypt
Patients applied
Trial Officials
Shereen E Abd Ellatif, MD
Principal Investigator
Faculty of medicine, zagazig university
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials